Skip to main content

Month: May 2022

Telos Corporation Announces First Quarter Results: Delivers $50.2 Million of Revenue and Expands Gross Margin by Over 1,100 Basis Points Year over Year; Turns Cash Flow Positive for the Trailing Twelve Month Period

Delivers Revenue of $50.2 Million, Above High End of Guidance Range Increased Gross Profit 30% Year over Year to $18.9 Million; Expanded Gross Margin Over 1,100 Basis Points Year over Year to 37.6% Generated $14.4 Million of Cash Flow from Operations and $0.5 Million of Free Cash Flow for the Trailing Twelve-Month Period Reaffirming Full Year GuidanceASHBURN, Va., May 10, 2022 (GLOBE NEWSWIRE) — Telos® Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, today announced financial results for the first quarter 2022. “We delivered $50.2 million of revenue in the first quarter of 2022, above the high end of our guidance range,” said John B. Wood, chairman and CEO, Telos. “Compared to the first quarter of 2021, we increased gross profit...

Continue reading

Ebix Announces Q1 2022 Revenues of $286.3 Million with 7% Sequential Growth and Diluted EPS of $0.62 with 24% Sequential Growth

JOHNS CREEK, Ga., May 10, 2022 (GLOBE NEWSWIRE) — Ebix, Inc. (NASDAQ: EBIX), a leading international supplier of on-demand software and e-commerce services to the insurance, financial services, travel, healthcare, and e-learning industries today announced the following results for the quarter ended March 31, 2022:Revenues of $286.3 million GAAP operating income of $30.1 million and Non-GAAP operating income of $33.8 million GAAP Diluted EPS of $0.62 and Non-GAAP diluted EPS of $0.76.Ebix will host a conference call to review its results today at 11:30 a.m. EDT (details below). Robin Raina, President & CEO, Ebix, Inc. said. “I am pleased with these results on many fronts. On a constant currency basis, our GAAP revenues grew year-over-year by 1% inspite of a 7% decline in prepaid gift card revenues in Q1 2022 as compared...

Continue reading

COMPASS Pathways plc announces first quarter 2022 financial results and business highlights

LONDON, May 10, 2022 (GLOBE NEWSWIRE) —Highlights:End of phase II meeting held with FDA Award of Innovation Passport as part of the UK MHRA Innovative Licensing and Access Pathway ILAP Finalising phase III in TRD program design to be ready for second half of 2022 Pioneering collaboration with King’s College London and South London and Maudsley NHS Foundation Trust, to create The Centre for Mental Health Research and Innovation in the UK Cash position at 31 March 2022 of $243.7 million Conference call today at 8:00am ET (1:00pm UK)COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2022 and gave an update on recent progress across its business. George...

Continue reading

Dream Finders Announces First Quarter 2022 Results

Homebuilding Revenues up 94%, Gross Margin Improvement of 380 Basis Points to 18.7%,Backlog of Sold Homes Increases to 7,413 Homes, Valued at $3.4 Billion JACKSONVILLE, Fla., May 10, 2022 (GLOBE NEWSWIRE) — Dream Finders Homes, Inc. (the “Company”, “Dream Finders” or “DFH”) (NASDAQ: DFH), one of the nation’s fastest-growing companies, announced its financial results for the first quarter ended March 31, 2022. First Quarter 2022 Highlights (As Compared to First Quarter 2021)Backlog of sold homes increased 105.2% to 7,413 homes valued at $3.4 billion, both Company records, compared to 3,612 homes valued at $1.4 billion Homebuilding revenues increased 93.6% to $662.5 million from $342.2 million Gross margin as a percentage of homebuilding revenues increased 380 basis points to 18.7% from 14.9% Pre-tax income increased 182.1% to...

Continue reading

Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results

Company to host a webcast today at 4:30 p.m. Eastern Time NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended March 31, 2022. “We are pleased with the continued advancement regarding our lead product candidate ANAVEX®2-73 in Alzheimer’s disease and Rett syndrome as we maintain our attention on execution across each of our clinical programs and overall business operations,” said Christopher U Missling, PhD, President and Chief Executive...

Continue reading

Katapult Announces First Quarter 2022 Financial Results

PLANO, Texas, May 10, 2022 (GLOBE NEWSWIRE) — Katapult Holdings, Inc. (“Katapult” or the “Company”) (NASDAQ: KPLT), an e-commerce-focused financial technology company, today reported its financial results for the first quarter ended March 31, 2022. First Quarter 2022 Financial and Operational Highlights:Recorded total revenue of $59.9 million in first quarter 2022 compared to $80.6 million in the prior year, a decrease of $20.7 million. $3.0 million of this decline was attributable to the Company’s adoption of ASC 842 as of January 1, 2022.Added 27 new merchants in the first quarter 2022.Continued high customer satisfaction with Net Promoter Score of 51 as of March 31, 2022 and rising to 64 at the end of April 2022. More than 49% of gross originations for first quarter 2022 came from repeat customers (customers who have originated...

Continue reading

Achilles Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

– Dosed first patient with higher-dose (Process 2) cNeT for advanced NSCLC (CHIRON) and initiated enrollment of cNeT + PD-1 inhibitor combination (THETIS Cohort B) for metastatic malignant melanoma – – Expanded global manufacturing by increasing capacity in the UK and establishing a US clinical manufacturing partnership – – Strong cash balance of $237 million supports all planned operations into 2H 2024 – LONDON, May 10, 2022 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2022, and recent business highlights. “We recently dosed the first patient with our higher-dose cNeT therapy in the CHIRON clinical...

Continue reading

Peloton Interactive, Inc. Reports Third Quarter Fiscal 2022 Financial Results

NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) — Peloton Interactive, Inc. (Nasdaq: PTON) has announced its financial results for third quarter 2022. Please visit the Peloton investor relations website https://investor.onepeloton.com/financial-information/quarterly-results to view the third quarter 2022 shareholder letter. Today the company will host a live audio webcast of its conference call to discuss the results at 8:30 a.m. ET. Additional Call Details: What: Peloton Third Quarter 2022 Earnings Conference Call When: Tuesday, May 10, 2022 Time: 8:30 a.m. ET Live Call: 1-866-777-2509 (US) or 1-412-317-5413 (international) Webcast: https://investor.onepeloton.com/financial-information/quarterly-results The archived webcast of the conference call will be available following the call. About Peloton Peloton is the leading interactive fitness...

Continue reading

Athenex Provides First Quarter 2022 Financial Results and Business Update

Reports 1Q product sales of $29.0M, up 42% year-over-year Encouraging interim update from ANCHOR study of KUR-502 presented at ASTCT with 60% overall response rate (ORR) and 6-month complete response (CR) rate of 29% in the NHL cohort Abstract for KUR-501 in GINAKIT2 study accepted at ASGCT; 25% (3/12) ORR with 2 out of 3 responses at dose level 4 (1×108 cells/m2) Corporate reorganization and cost savings initiatives well underway, demonstrated by 28% and 39% reduction in SG&A expenses and R&D expenses, respectively, over the prior year period Raising full-year 2022 product revenue guidance range to 20-25% growth from previous range of 15-20% growth compared to 2021 Management to host conference call and webcast today at 8:00 a.m. ETBUFFALO, N.Y., May 10, 2022 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ: ATNX),...

Continue reading

First Watch Restaurant Group, Inc. Reports Strong Q1 2022 Financial Results

Same-restaurant sales growth of 27.2% driven by same-restaurant traffic growth of 21.9%Income from operations margin of 4.5% and restaurant level operating profit margin of 19.6%7 system-wide restaurants opened across 5 states BRADENTON, Fla., May 10, 2022 (GLOBE NEWSWIRE) — First Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch” or the “Company”), the leading Daytime Dining concept serving breakfast, brunch and lunch, today reported financial results for the thirteen weeks ended March 27, 2022 (“Q1 2022”) and reiterated its fiscal year 2022 guidance. “I’m pleased that First Watch’s track record of exceptional operating performance has continued into 2022. We increased total revenues by 36.1% over the first quarter of the prior year, driven by same-restaurant sales growth of 27.2% and same-restaurant traffic growth of...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.